ABT
ABBOTT LABORATORIES
Key Financials
Operating Income
$8.1B
↑ 18.0%
Gross Profit
$4.4B
↑ 3.8%
Revenue
$44.3B
↑ 5.7%
Net Income
$6.5B
↓ 51.3%
EPS (Diluted)
$3.72
↓ 51.3%
Total Assets
$86.7B
↑ 6.5%
Shareholders' Equity
$52.1B
↑ 9.4%
Cash & Equivalents
$8.5B
↑ 11.9%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 4/17/2026 | View on SEC |
| 8-K | 4/16/2026 | View on SEC |
| 4 | 4/2/2026 | View on SEC |
| 4 | 4/2/2026 | View on SEC |
| 4 | 4/2/2026 | View on SEC |
| 4 | 4/2/2026 | View on SEC |
| 4 | 4/2/2026 | View on SEC |
| SCHEDULE 13G/A | 3/26/2026 | View on SEC |
| 4 | 3/25/2026 | View on SEC |
| 3 | 3/25/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ABT |
| Company Name | ABBOTT LABORATORIES |
| CIK | 1800 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | NYSE |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | IL |
| Phone | 2246676100 |